- A succinic acid to a venlafaxine monohydrate new crystal and preparation method (by machine translation)
-
The invention relates to a venlafaxine succinate monohydrate of the new crystalline form VI, the crystalline form VI of the X - ray powder diffraction pattern includes the following 2 θ angle peaks represented in: 5.14 °, 10 . 26°, 13 . 16°, 14 . 28°, 16 . 67°, 19 . 14°, 20 . 60°, 23 . 30° and 25.86 °. The invention also relates to a method for preparing said form VI. The invention VI crystalline form is easy to prepare, has good stability and preparation moldability, and compared with the yu Jingxing I, II and M, crystalline form VI production yield optimum, the prepared tablet release curve closer to the commercial preparation. (by machine translation)
- -
-
Paragraph 0059; 0060
(2017/06/20)
-
- Crystalline polymorphs of desvenlafaxine succinate and their preparations
-
The present invention is directed to two new polymorph Form V and Form F of desvenlafaxine succinate, to processes of their preparations, pharmaceutical composition comprising such materials and their use in therapy. Form V is prepared from recrystallizing desvenlafaxine succinate in a mixture of tetrahydrofuran and ethanol. Form F is obtained from recrystallization of desvenlafaxine succinate in a mixture of cyclohexane and polar solvents such as ethanol, THF, methanol or isopropyl alcohol.
- -
-
Page/Page column 9
(2008/12/07)
-
- NOVEL HYDRATE FORM OF O-DESMETHYL VENLAFAXINE SUCCINATE
-
The present invention relates to a novel hydrate form of O-desmethyl venlafaxine succinate. The present invention further relates to processes for the preparation of the novel hydrate form, pharmaceutical compositions comprising it, second medical uses of the novel hydrate form, and methods using it for treating diseases such as generalised anxiety disorder, anxiety, depressive disorder, depression and panic disorder.
- -
-
Page/Page column 10
(2008/06/13)
-
